AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 31.71 |
Market Cap | 1.14B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.47 |
PE Ratio (ttm) | -115.36 |
Forward PE | n/a |
Analyst | Buy |
Ask | 56.57 |
Volume | 97,135 |
Avg. Volume (20D) | 258,973 |
Open | 54.11 |
Previous Close | 53.93 |
Day's Range | 53.35 - 54.48 |
52-Week Range | 52.50 - 70.81 |
Beta | undefined |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development a...
Analyst Forecast
According to 7 analyst ratings, the average rating for ANIP stock is "Buy." The 12-month stock price forecast is $78.5, which is an increase of 44.78% from the latest price.
Next Earnings Release
Analysts project revenue of $175.12M, reflecting a 33.02% YoY growth and earnings per share of 0.31, making a -69.00% decrease YoY.
2 months ago · seekingalpha.com
ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call TranscriptANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz ...